Ivo Ditah1, Fausta Ditah2, Pardha Devaki3, Oforbuike Ewelukwa4, Chobufo Ditah5, Basile Njei6, Henry N Luma5, Michael Charlton7. 1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States. Electronic address: Ditah.ivo@mayo.edu. 2. Division of Gastroenterology Hepatology, and Nutrition, Vanderbilt University School of Medicine, United States. 3. Wayne State University, Detroit, MI, United States. 4. Wright State University, Dayton, OH, United States. 5. Hopital General Douala, Douala, Cameroon. 6. University of Connecticut School of Medicine, Birmingham, CT, United States. 7. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.
Abstract
BACKGROUND & AIMS: In light of the dramatically changing hepatitis C therapeutic landscape, knowledge of the current burden of HCV infection in the general population of the United States is critical. METHODS: The National Health and Nutrition Examination survey collects nationally representative data on HCV infection in the civilian population of the United States. Data from 2001 to 2010 were combined for this study. HCV testing was completed in 38,025 participants. RESULTS: The prevalence of anti-HCV in the United Sates decreased from 1.9% (95% CI 1.5%-2.5%) in 2001-2002 to 1.3% (95% CI 0.9%-1.8%) in 2005-2006, and remained stable up to 2010. About 67% of all infected persons were positive for HCV RNA, indicating 2.3 million people with chronic HCV infection, of whom 68% have genotype 1. Seventy percent of infected persons were born between 1945 and 1965, with prevalence of 3.5% (95% CI 2.2%-4.8%). The stable rate since 2006 is mostly related to prevalent cases and foreign born persons migrating into US. Other important risk factors include less education and low economic status. Race, HIV status, number of sexual partners, and blood transfusions are no longer associated with HCV infection. CONCLUSIONS: As of 2010, approximately 2.3 million persons were chronically infected with Hepatitis C in the US. Most of those infected are prevalent, rather than incident cases. The prevalence of HCV was on the decline, but has stabilized since 2006. Future studies should explore reasons for no decline in HCV prevalence since 2006.
BACKGROUND & AIMS: In light of the dramatically changing hepatitis C therapeutic landscape, knowledge of the current burden of HCV infection in the general population of the United States is critical. METHODS: The National Health and Nutrition Examination survey collects nationally representative data on HCV infection in the civilian population of the United States. Data from 2001 to 2010 were combined for this study. HCV testing was completed in 38,025 participants. RESULTS: The prevalence of anti-HCV in the United Sates decreased from 1.9% (95% CI 1.5%-2.5%) in 2001-2002 to 1.3% (95% CI 0.9%-1.8%) in 2005-2006, and remained stable up to 2010. About 67% of all infected persons were positive for HCV RNA, indicating 2.3 million people with chronic HCV infection, of whom 68% have genotype 1. Seventy percent of infected persons were born between 1945 and 1965, with prevalence of 3.5% (95% CI 2.2%-4.8%). The stable rate since 2006 is mostly related to prevalent cases and foreign born persons migrating into US. Other important risk factors include less education and low economic status. Race, HIV status, number of sexual partners, and blood transfusions are no longer associated with HCV infection. CONCLUSIONS: As of 2010, approximately 2.3 million persons were chronically infected with Hepatitis C in the US. Most of those infected are prevalent, rather than incident cases. The prevalence of HCV was on the decline, but has stabilized since 2006. Future studies should explore reasons for no decline in HCV prevalence since 2006.
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton Journal: Gastroenterology Date: 2017-01-11 Impact factor: 22.682
Authors: Rok Seon Choung; Ivo C Ditah; Ashley M Nadeau; Alberto Rubio-Tapia; Eric V Marietta; Tricia L Brantner; Michael J Camilleri; S Vincent Rajkumar; Ola Landgren; James E Everhart; Joseph A Murray Journal: Am J Gastroenterol Date: 2015-02-10 Impact factor: 10.864
Authors: Kian Bichoupan; Valerie Martel-Laferriere; David Sachs; Michel Ng; Emily A Schonfeld; Alexis Pappas; James Crismale; Alicia Stivala; Viktoriya Khaitova; Donald Gardenier; Michael Linderman; Ponni V Perumalswami; Thomas D Schiano; Joseph A Odin; Lawrence Liu; Alan J Moskowitz; Douglas T Dieterich; Andrea D Branch Journal: Hepatology Date: 2014-08-25 Impact factor: 17.425
Authors: R Irvin; A McAdams-Mahmoud; D Hickman; J Wilson; W Fenwick; I Chen; N Irvin; O Falade-Nwulia; M Sulkowski; R Chaisson; D L Thomas; S H Mehta Journal: J Community Med Health Educ Date: 2016-05-30
Authors: Lauren J Stockman; James Greer; Ryan Holzmacher; Beth Dittmann; Scott A Hoftiezer; Lori E Alsum; Audrey Prieve; Ryan P Westergaard; Sheila M Guilfoyle; James M Vergeront Journal: Public Health Rep Date: 2016 Jul-Aug Impact factor: 2.792